

RECEIVED
CENTRAL FAX CENTER

Application No. 10/535,325 - - - - 6

AUG 02 2007

Remarks

In response to the requirement for restriction, applicants hereby elect for further prosecution at this time the claims Group I, i.e., claims 1-13 and 21-28 directed to methods for treating a myocardial infarction with a Src family tyrosine kinase inhibitor.

As to the further requirement to elect a species, applicants hereby elect AGL 1872, also sometimes referred to as PP1.

The foregoing elections are made without traverse.

Claims 1-6, 10-13, 21-28, 34 and 35 read on the elected species.


Claims 29-33, inclusive, are canceled without prejudice.

New claims 34 and 35 are added directed to the elected species. In view of the cancellation of claims 29-33, inclusive, no extra claim fee is believed to be due.

Early action on the merits is solicited.

Respectfully submitted,

August 2, 2007

By 
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT is being transmitted by facsimile transmission to Fax No. 571-273-8300 on August 2, 2007.


Talivaldis Cepuritis (Reg. No. 20,818)